West nile virus laboratory tests

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

In 1999 in the U.S., the sensitivity of polymerase chain reaction (PCR) tests of CSF for the diagnosis of human WN encephalitis cases was only 57%; more recent statistics are currently unavailable. Thus, PCR for the diagnosis of WN viral infections of the human central nervous system (CNS) continues to be experimental and should not replace tests for the detection of WNV-specific antibody in CSF and serum, tests that are far more sensitive.

A high clinical suspicion for arboviral encephalitis should be encouraged among health care providers. When the diagnosis is in doubt, appropriate clinical specimens should be submitted to CDC or another laboratory capable of performing reliable serologic testing for antibodies to domestic arboviruses. Testing of CSF and paired acute- and convalescent-phase serum samples should be strongly encouraged to maximize the accuracy of serologic results.

Laboratory Findings

The basic laboratory diagnostic tests—and how they should be used at the national, state, and local level—are outlined below. The initial designation of reference and regional laboratories that can do all testing will be based on the availability of biosafety level 3 (BSL3) containment facilities.

Serologic Laboratory Diagnosis

Accurate interpretation of serologic findings requires knowledge of the specimen. For human specimens the following data must accompany specimens submitted for serology before testing can proceed or results can be properly interpreted and reported:

1) symptom onset date (when known);

2) date of sample collection;

3) unusual immunological status of patient (e.g., immunosuppression);

4) state and county of residence;

5) travel history in flavivirus-endemic areas;

6) history of prior vaccination against flavivirus disease (e.g., yellow fever, Japanese encephalitis, or Central European encephalitis); and

7) brief clinical summary including clinical diagnosis (e.g., encephalitis, aseptic meningitis).

1. Human

a) Commercial kits for human serologic diagnosis of WNV infection are currently in development. Until these kits are available, the CDC-defined IgM and IgG ELISA should be the front-line tests for serum and CSF. These ELISA tests are the most sensitive screening assays available. The HI and indirect immunofluorescent antibody (IFA) test may also be used to screen samples for flavivirus antibodies. Laboratories performing HI assays need be aware that the recombinant WNV antigens produced to date are not useful in the HI test; mouse brain source antigen (available from CDC) must be used in HI tests. The recombinant WNV antigen is available from commercial sources.

b) To date, the prototype WNV strains Eg101 or NY99 strains have performed equally well as antigens in diagnostic tests for WNV in North America.

c) To maintain Clinical Laboratory Improvements Amendments (CLIA) certification, CLIA recommendations for positive and negative ranges should be followed, and laboratories doing WNV testing should participate in a proficiency testing program through experienced reference laboratories; CDC’s Division of Vector-Borne Infectious Diseases in Fort Collins, Colorado and the National Veterinary Services Laboratories in Ames, Iowa both offer this type of program.

d) Because the ELISA can cross-react between flaviviruses (e.g., SLE, dengue, yellow fever, WN), it should be viewed as a screening test only. Initial serologically positive samples should be confirmed by neutralization test. Specimens ubmitted for arboviral serology should also be tested against other arboviruses known to be active or be present in the given area (e.g., test against SLE, WN and EEE viruses in Florida).

References

Template:WS